Bone marrow-derived mesenchymal stem cells and their exosomes in Alzheimer's disease: Mechanisms and therapeutic potential
New Cell · 31.03.2026
DOI: 10.61958/ncjg8269 ↗Kurz gefasst
Fachartikel in der Zeitschrift New Cell, online erschienen am 31.03.2026. Verfasst von Rui Su und 1 weiteren Autor:innen. Die Arbeit nennt 105 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β (Aβ) deposition, tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, and blood-brain barrier (BBB) impairment, for which effective disease-modifying therapies remain lacking. Bone marrow-derived mesenchymal stem cells (BMSCs) and their derived exosomes (BMSC-exos) have emerged as promising therapeutic candidates due to their multifaceted biological properties. This review systematically summarizes the pathological mechanisms of AD and highlights the therapeutic potential of BMSCs and BMSC-exos. BMSCs exert neuroprotective effects through multiple mechanisms, including modulation of neuroinflammation via inhibition of glial activation and pro-inflammatory cytokine release, attenuation of oxidative stress, suppression of neuronal apoptosis, and promotion of neuroplasticity and neurogenesis through secretion of neurotrophic factors such as brain-derived neurotrophic factor (BDNF). Additionally, BMSCs contribute to the clearance of pathological proteins and restoration of neurovascular unit integrity. Early-phase clinical trials demonstrate favorable safety and tolerability profiles, although evidence of efficacy remains preliminary due to limited sample sizes and short follow-up durations. Importantly, BMSC-exos represent a cell-free therapeutic strategy with advantages including low immunogenicity, enhanced BBB penetration, and ease of administration. Preclinical studies indicate that BMSC-exos can ameliorate cognitive deficits, reduce Aβ and tau pathology, suppress neuroinflammation, and enhance synaptic function, largely mediated by bioactive cargos such as microRNAs. Collectively, both BMSCs and their exosomes exhibit significant therapeutic potential for AD; however, further large-scale clinical studies are required to establish optimal treatment protocols and confirm long-term efficacy.
Zitieren
APA
Su, R., & Yang, Q. (2026). Bone marrow-derived mesenchymal stem cells and their exosomes in Alzheimer's disease: Mechanisms and therapeutic potential. New Cell. https://doi.org/10.61958/ncjg8269
Vancouver
Su R, Yang Q. Bone marrow-derived mesenchymal stem cells and their exosomes in Alzheimer's disease: Mechanisms and therapeutic potential. New Cell. 2026. doi:10.61958/ncjg8269
BibTeX
@article{Su2026,
author = {Su, Rui and Yang, Qing-Yu},
title = {Bone marrow-derived mesenchymal stem cells and their exosomes in Alzheimer's disease: Mechanisms and therapeutic potential},
journal = {New Cell},
year = {2026},
doi = {10.61958/ncjg8269}
}
EUVIMED